“Traveler’s Diarrhea Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Traveler’s Diarrhea market.
Traveler’s Diarrhea Market Outlook
According to DelveInsight, Traveler’s Diarrhea market in 7MM is expected to increase in the study period 2017-2030 from USD 1,717 Million in 2017 owing to the upcoming therapies.
The United States accounts for the largest Traveler’s Diarrhea market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan owing to the largest number of incident population.
Traveler’s Diarrhea Pipeline Drugs
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Traveler’s Diarrhea key players involved in developing targeted therapeutics.
The late stage product Bismuth Subsalicylate has emerged as a promising option to enter the market in 2021 for Traveler’s Diarrhea. Another mid stage product Etvax is a vaccine against diarrheal disease caused by ETEC expected to enter the market by 2023.
In the report, a detailed Traveler’s Diarrhea pipeline landscape is provided including the disease overview and Traveler’s Diarrhea treatment guidelines. The assessment part of the report embraces in-depth Traveler’s Diarrhea commercial assessment and clinical assessment of the Traveler’s Diarrhea pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Traveler’s Diarrhea collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Scope of the report
- Overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type, including all clinical and nonclinical stages.
- Detailed profiles of Traveler’s Diarrhea therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Traveler’s Diarrhea research and development progress and trial details
- Coverage of dormant and discontinued pipeline projects along with the opinions and reasons
Table of Contents
1. Report Introduction
2. Traveler’s Diarrhea
3. Traveler’s Diarrhea Current Treatment Patterns
4. Traveler’s Diarrhea – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Traveler’s Diarrhea Late Stage Products (Phase-III)
7. Traveler’s Diarrhea Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Traveler’s Diarrhea Discontinued Products
13. Traveler’s Diarrhea Product Profiles
14. Traveler’s Diarrhea Key Companies
15. Traveler’s Diarrhea Key Products
16. Dormant and Discontinued Products
17. Traveler’s Diarrhea Unmet Needs
18. Traveler’s Diarrhea Future Perspectives
19. Traveler’s Diarrhea Analyst Review
21. Report Methodology
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Address:304 S. Jones Blvd #2432
Country: United States